These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 11099897

  • 1. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A.
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [Abstract] [Full Text] [Related]

  • 2. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ, Neocleous K, Kolnagou A.
    Drug Saf; 2003 Dec; 26(8):553-84. PubMed ID: 12825969
    [Abstract] [Full Text] [Related]

  • 3. Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.
    Kontoghiorghes GJ.
    Indian J Pediatr; 1993 Dec; 60(4):485-507. PubMed ID: 8262586
    [Abstract] [Full Text] [Related]

  • 4. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Aug 21; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 6. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ, Kolnagou A.
    Haematologica; 2006 Jun 21; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [Abstract] [Full Text] [Related]

  • 7. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; (8):CD004839. PubMed ID: 23966105
    [Abstract] [Full Text] [Related]

  • 8. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA, Foster RH.
    Drugs; 1999 Sep 21; 58(3):553-78. PubMed ID: 10493280
    [Abstract] [Full Text] [Related]

  • 9. A risk-benefit assessment of iron-chelation therapy.
    Porter JB.
    Drug Saf; 1997 Dec 21; 17(6):407-21. PubMed ID: 9429839
    [Abstract] [Full Text] [Related]

  • 10. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul 21; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 11. New chelation therapies and emerging chelating drugs for the treatment of iron overload.
    Kontoghiorghes GJ.
    Expert Opin Emerg Drugs; 2006 Mar 21; 11(1):1-5. PubMed ID: 16503822
    [Abstract] [Full Text] [Related]

  • 12. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 May 08; 5(5):CD012349. PubMed ID: 29737522
    [Abstract] [Full Text] [Related]

  • 13. Iron chelation therapy.
    Hoffbrand AV, Wonke B.
    J Intern Med Suppl; 1997 May 08; 740():37-41. PubMed ID: 9350180
    [Abstract] [Full Text] [Related]

  • 14. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
    Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Res (Stuttg); 2017 Jul 08; 67(7):404-411. PubMed ID: 28320041
    [Abstract] [Full Text] [Related]

  • 15. Clinical use, therapeutic aspects and future potential of deferiprone in thalassemia and other conditions of iron and other metal toxicity.
    Kontoghiorghes GJ.
    Drugs Today (Barc); 2001 Jan 08; 37(1):23-35. PubMed ID: 12783095
    [Abstract] [Full Text] [Related]

  • 16. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ.
    Analyst; 1995 Mar 08; 120(3):845-51. PubMed ID: 7741239
    [Abstract] [Full Text] [Related]

  • 17. [Iron chelation in 1998].
    de Montalembert M.
    Transfus Clin Biol; 1998 Oct 08; 5(5):353-6. PubMed ID: 9836396
    [Abstract] [Full Text] [Related]

  • 18. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A.
    Curr Med Chem; 2005 Oct 08; 12(23):2663-81. PubMed ID: 16305464
    [Abstract] [Full Text] [Related]

  • 19. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A, Kontoghiorghes GJ.
    Front Biosci (Landmark Ed); 2018 Jan 01; 23(6):1082-1098. PubMed ID: 28930590
    [Abstract] [Full Text] [Related]

  • 20. Pharmacotherapy of iron overload in thalassaemic patients.
    Ceci A, Felisi M, De Sanctis V, De Mattia D.
    Expert Opin Pharmacother; 2003 Oct 01; 4(10):1763-74. PubMed ID: 14521486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.